Search
Pancreatic Cancer Clinical Trials
A listing of 145 Pancreatic Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
61 - 72 of 145
There are currently 145 active clinical trials seeking participants for Pancreatic Cancer research studies. The states with the highest number of trials for Pancreatic Cancer participants are California, New York, Illinois and Texas.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Healthy Volunteer Clinical Studies
Recruiting
Find a study looking for volunteers at a study site near you! Some trials offer compensation for time and travel. Click through to learn more about study opportunities.
Conditions:
Healthy
Healthy Volunteers
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
Recruiting
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other solid tumors that express CEA and have lost HLA-A*02 expression.
The main questions this study aims to answer are:
Phase 1: What is the maximum or recommended dose of A2B530 that is safe for patients
Phase 2: Does the recommended dose of A2B530 kill the solid tumor cel... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/07/2024
Locations: Banner Health, Gilbert, Arizona +9 locations
Conditions: Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Recruiting
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: UCLA, Los Angeles, California +11 locations
Conditions: Metastatic Cancer, Solid Tumor, Colorectal Cancer, Pancreatic Cancer, Urothelial Carcinoma, Head and Neck Cancer
A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus
Recruiting
The main goal of this study is to explore the relationship between new-onset diabetes mellitus/deteriorating diabetes and a subsequent diagnosis of pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early stage pancreatic cancer or precursor lesions. Participants will be asked to donate a blood sample at specific intervals for the creation of a bio-bank necessary for the development of a blood based screening test for pan... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
03/29/2024
Locations: Nuvance Health, Norwalk, Connecticut
Conditions: Pancreatic Cancer, Pancreatic Neoplasms
Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer
Recruiting
This trial will be a non-randomized, Phase I trial to evaluate safety, tolerability, biodistribution, radiation dosimetry, pharmacokinetics and PET imaging properties following an infusion of 37 MBq (1 mCi) of 89Zr-labeled hNd2* (NMK89) in patients with pancreatic cancer that are positive for MUC5AC. Image acquisition is conducted using a PET/CT machine.
* hNd2: Recombinant humanized Nd2 (anti-human MUC5AC monoclonal antibody)
Gender:
All
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: Moffitt Cancer Center, Tampa, Florida +2 locations
Conditions: Pancreatic Cancer
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
Recruiting
RATIONALE: Studying samples of tissue, blood, urine, stool, and other biological fluids from patients with cancer and from healthy volunteers undergoing colonoscopy or endoscopy may help doctors identify and learn more about biomarkers related to cancer.
PURPOSE: This research study is looking at gastrointestinal biomarkers in tissue and biological fluid samples from patients and participants undergoing colonoscopy, endoscopy, or surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Veterans Affairs Medical Center - Nashville, Nashville, Tennessee +1 locations
Conditions: Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Precancerous Condition
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Recruiting
The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +15 locations
Conditions: Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer
PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic Disease
Recruiting
The specific aims of this project are to create a registry, as well as a biospecimen bank for individuals with pancreatic disease (e.g. pancreatic adenocarcinoma, pancreatitis, intraductal papillary mucinous neoplasm (IPMN) mucinous cystic neoplasm (MCN), and pancreatic intraepithelial neoplasia (PanIN) or have been determined to be at high-risk for pancreatic cancer. Biospecimen can be defined as blood, urine, tissue, stool, or saliva samples. Therefore, no hypothesis is to be tested. The perso... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/26/2024
Locations: Columbia University Medical Center, New York, New York
Conditions: Pancreatic Cancer
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Recruiting
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation.
The main question[s] it aims to answer are:
the recommended dose for Phase 2
to evaluate the safety and tolerability of the combination therapy
to determine the pharmacokinetics of TNG260
to evaluate the initial antineoplastic activity
Participants will receive study treatment until they experience an... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: UCLA Hematology/Oncology, Santa Monica, California +8 locations
Conditions: Non Small Cell Lung Cancer, Solid Tumors, Adult, Endometrial Cancer, Pancreatic Cancer, Cervical Cancer, Breast Cancer, Carcinoma of Unknown Primary
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
Recruiting
This is a randomized trial to compare the standard echoendoscope with the newly developed EndoSound Visual System in the evaluation of lesions in the gastrointestinal tract.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/25/2024
Locations: Orlando Health, Orlando, Florida
Conditions: Pancreatic Disease, Pancreatic Cancer, Pancreatic Cyst, Gastrointestinal Tumor, Bile Duct Diseases, Bile Duct Cancer, Lymph Node Disease, Submucosal Tumor of Gastrointestinal Tract, Gastrointestinal Cancer
A Study of CDX-585 in Patients With Advanced Malignancies
Recruiting
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: George Washington University Cancer Center, Washington, District of Columbia +3 locations
Conditions: Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors
Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients
Recruiting
The purpose of the study is to assess the feasibility and participant satisfaction with the Support through Remote Observation and Nutrition Guidance (STRONG) program. The program provides enhanced dietician access and nutrition support for participants living with pancreatic cancer who are receiving chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Pancreatic Cancer
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Recruiting
The purpose of this study is to evaluate the safety and clinical activity of tislelizumab (an anti-PD-1 antibody) in combination with SX-682 (a CXCR1/2 inhibitor) in subjects with newly diagnosed and surgically resectable pancreatic adenocarcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Johns Hopkins SKCCC, Baltimore, Maryland
Conditions: Pancreatic Cancer
61 - 72 of 145